The multidisciplinary management of cholangiocarcinoma

IF 6.1 2区 医学 Q1 ONCOLOGY Cancer Pub Date : 2022-11-16 DOI:10.1002/cncr.34541
Kim C. Ohaegbulam MD, PhD, Yilun Koethe MD, Alice Fung MD, FSAR, Skye C. Mayo MD, MPH, FACS, Aaron J. Grossberg MD, PhD, Emerson Y. Chen MD, Kaveh Sharzehi MD, MS, Adel Kardosh MD, PhD, Khashayar Farsad MD, PHD, Flavio G. Rocha MD, FACS, FSSO, Charles R. Thomas MD, Nima Nabavizadeh MD
{"title":"The multidisciplinary management of cholangiocarcinoma","authors":"Kim C. Ohaegbulam MD, PhD,&nbsp;Yilun Koethe MD,&nbsp;Alice Fung MD, FSAR,&nbsp;Skye C. Mayo MD, MPH, FACS,&nbsp;Aaron J. Grossberg MD, PhD,&nbsp;Emerson Y. Chen MD,&nbsp;Kaveh Sharzehi MD, MS,&nbsp;Adel Kardosh MD, PhD,&nbsp;Khashayar Farsad MD, PHD,&nbsp;Flavio G. Rocha MD, FACS, FSSO,&nbsp;Charles R. Thomas MD,&nbsp;Nima Nabavizadeh MD","doi":"10.1002/cncr.34541","DOIUrl":null,"url":null,"abstract":"<p>Cholangiocarcinoma is a lethal malignancy of the biliary epithelium that can arise anywhere along the biliary tract. Surgical resection confers the greatest likelihood of long-term survivability. However, its insidious onset, difficult diagnostics, and resultant advanced presentation render the majority of patients unresectable, highlighting the importance of early detection with novel biomarkers. Developing liver-directed therapies and emerging targeted therapeutics may offer improved survivability for patients with unresectable or advanced disease. In this article, the authors review the current multidisciplinary standards of care in resectable and unresectable cholangiocarcinoma, with an emphasis on novel biomarkers for early detection and nonsurgical locoregional therapy options.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"129 2","pages":"184-214"},"PeriodicalIF":6.1000,"publicationDate":"2022-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cncr.34541","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 3

Abstract

Cholangiocarcinoma is a lethal malignancy of the biliary epithelium that can arise anywhere along the biliary tract. Surgical resection confers the greatest likelihood of long-term survivability. However, its insidious onset, difficult diagnostics, and resultant advanced presentation render the majority of patients unresectable, highlighting the importance of early detection with novel biomarkers. Developing liver-directed therapies and emerging targeted therapeutics may offer improved survivability for patients with unresectable or advanced disease. In this article, the authors review the current multidisciplinary standards of care in resectable and unresectable cholangiocarcinoma, with an emphasis on novel biomarkers for early detection and nonsurgical locoregional therapy options.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
胆管癌的多学科治疗
胆管癌是一种胆道上皮的致死性恶性肿瘤,可发生在胆道的任何地方。手术切除提供了最大的长期生存的可能性。然而,它的发病隐匿,诊断困难,以及由此导致的晚期表现使得大多数患者无法切除,突出了用新型生物标志物早期检测的重要性。发展肝脏定向治疗和新兴的靶向治疗可能会提高不可切除或晚期疾病患者的生存率。在这篇文章中,作者回顾了目前可切除和不可切除胆管癌的多学科治疗标准,重点是早期发现的新型生物标志物和非手术局部治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer
Cancer 医学-肿瘤学
CiteScore
13.10
自引率
3.20%
发文量
480
审稿时长
2-3 weeks
期刊介绍: The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society. CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research
期刊最新文献
Glioma mutational signatures associated with haloalkane exposure are enriched in firefighters Correction to “Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (EAGLES, Korean Cancer Study Group UN18-06)” Health literacy and all-cause mortality among cancer patients Remedying Black cancer disparities with clinical research prioritization The effect of online cognitive behavioral therapy for insomnia in adolescents and young adults after childhood cancer: Results from a randomized controlled trial
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1